Lipocine is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.71 – a decrease of 3.68% over the previous week. Lipocine employs 17 staff and has a trailing 12-month revenue of around $4.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.71 |
|---|---|
| 52-week range | $2.38 - $11.79 |
| 50-day moving average | $4.97 |
| 200-day moving average | $5.26 |
| Wall St. target price | $21.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.75 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.71 from 2024-11-20
| 1 week (2024-11-14) | -9.60% |
|---|---|
| 1 month (2024-10-21) | -15.29% |
| 3 months (2024-08-21) | 31.56% |
| 6 months (2024-05-21) | -28.31% |
| 1 year (2023-11-21) | 87.65% |
|---|---|
| 2 years (2022-11-21) | -38.57% |
| 3 years (2021-11-19) | 19.89 |
| 5 years (2019-11-21) | 6.8901 |
| Revenue TTM | $4.8 million |
|---|---|
| Gross profit TTM | $500,000 |
| Return on assets TTM | -22.67% |
| Return on equity TTM | -34.12% |
| Profit margin | -176.8% |
| Book value | $3.83 |
| Market Capitalization | $27.9 million |
TTM: trailing 12 months
We're not expecting Lipocine to pay a dividend over the next 12 months.
Lipocine's shares were split on a 1:17 basis on 11 May 2023 . So if you had owned 17 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 1600% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.
Over the last 12 months, Lipocine's shares have ranged in value from as little as $2.38 up to $11.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 1.188. This would suggest that Lipocine's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Lipocine Inc. , a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.